期刊文献+

临床药师参与抗菌药物相关性腹泻治疗的药学研究

Pharmaceutical research on clinical pharmacists participating in treatment of antibiotic associated diarrhea
下载PDF
导出
摘要 目的探讨临床药师在临床药物治疗中所发挥的作用。方法回顾分析该院2013—2015年20例抗菌药物相关性腹泻病例特点和临床药师参与治疗的资料。结果20例患者,治愈19例,死亡1例,死亡患者因其伴发肝门胆总管癌,尽管口服使用了去甲万古霉素治疗,在腹泻症状好转后,还是未能挽救患者的生命。其余患者停用原抗菌药物,加用口服去甲万古霉素0.4g,每6小时1次。同时服用调整肠道菌群的药物(布拉氏酵母菌或干酵母)和胃黏膜保护剂(蒙脱石散)。结论临床药师能协助医师确定或调整用药方案,其在医疗团队中的作用正逐渐被临床认可。 Objective To discuss the role of clinical pharmacists playing in clinical medication treat- ment. Methods The characteristics of 20 cases of antibiotic associated diarrhea in our hospital from 2013 to 2015 and the data of the clinical pharmacists participating in the treatment were retrospectively analyzed. Re- suits Among 20 cases, 19 cases were cured,but 1 case died due to complicating porta common bile duct cancer, although taking demethylvancomycin,the patient's life was not rescued after the diarrhea symptoms improvement. Other cases stopped original antibacterial drugs and took oral demethylvancomycin 0.4 g, once per 6 h. A the same time the drugs for adjusting intestinal flora (Saccharomyces boulardii or Saccharated Yeast Tablets) and gastric mucosal protective agent (Montmorillonite Powder). Conclusion The clinical pharmacists can assisted doctor determine or adjust the medication scheme, their role in the medical team is gradually accepted by clinic.
作者 张芹 Zhang Qin(Hebi Municipal People's Hospital, Hebi, Henan 458030, Chin)
机构地区 鹤壁市人民医院
出处 《现代医药卫生》 2016年第B08期13-14,共2页 Journal of Modern Medicine & Health
关键词 药剂师 抗菌药 腹泻/治疗 万古霉素 药学 Pharmacists Anti-bacterial agents Diarrhea/therapy Vancomycin Pharmacy
  • 相关文献

参考文献5

二级参考文献38

  • 1王成怀,邝欣,韩伟.兰州市婴幼儿艰难梭菌带菌状况[J].微生物学免疫学进展,1994,22(1):2-5. 被引量:4
  • 2Doron SI, Hibberd PL, Gorbach SL. Probiotics for prevention of antibiotic- associated diarrhea [ J ]. J Clin Gastroenterol, 2008,42 ( Suppl 2) : 58.
  • 3Mabasa VH, Malyuk DL, Tung A, et al. Using clinical pharmacy sup- port technicians to optimize pharmaceutical care in the intensive care unit [J]. Can J Hosp Pharm,2010,63(1) :41.
  • 4Kazanowski M, Smolarek S, Kinnarney F, et al. Clostridium difficile : epldemiology, diagnostic and therapeutic possibilities - a systematic review[ J]. Tech Coloproctol, 2014, 18 (3) : 223 - 232.
  • 5Chung CH, Wu C J, Lee HC, et al. Clostridium difficile infection at a medical center in southern Taiwan: incidence, clinical features and prognosis[J]. J Microbiol Immunol Infect, 2010, 43 ( 2 ) : 119 - 125.
  • 6Burke KE, Lamont JT. Clostridium difficile infection: a worldwide disease[J]. Gut Liver, 2014, 8(1): 1-6.
  • 7Zheng L, Keller SF, Lyerly DM, et al. Muhicenter evaluation of a new screening test that detects Clostridium difficile in fecal speci- mens[ J ]. J Clin Microbiol, 2004, 42 (8) : 3837 - 3840.
  • 8Bassetti M, Villa G, Pecori D, et al. Epidemiology, diagnosis and treatment of Clostridium dlfficile infection [ J ]. Expert Rev Anti Infect Ther, 2012, 10(12) : 1405 -1423.
  • 9Wu X, Hurdle JG. The Clostridium difficile proline racemase is not essential for early logarithmic growth and infection[J]. Can J Microbiol, 2014, 60(4): 251 -254.
  • 10Kenneley IL. Clostridium difficile infection is on the rises 33. Am J Nuts, 2014, 114(3) : 62 -67.

共引文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部